Table 2.
Estimated biological treatment costs.
| Biological therapies | Year 1 | Year 2 | ||
|---|---|---|---|---|
| Abatacept (250 mg vial) | 1st 6 months | 2nd 6 months | 1st 6 months | 2nd 6 months |
| Estimated number of vials per year | 37.8 | 35.1 | ||
| Infusion cost/IV infusion | 56.69 € | 56.69 € | ||
| Estimated reimbursement cost per year | 13,449.86 € | 12,489.15 € | ||
| Estimated cost per six months (26 weeks) | 6,724.93 € | 6,724.93 € | 5,764.22 € | 6,724.93 € |
| Adalimumab (40 mg syringe) | 1st 6 months | 2nd 6 months | 1st 6 months | 2nd 6 months |
| Estimated number of prefilled syringes per year | 26 | 26 | ||
| Estimated reimbursement cost per year | 13,367.77 € | 13,367.77 € | ||
| Estimated cost per six months (26 weeks) | 6,683.89 € | 6,683.89 € | 6,683.89 € | 6,683.89 € |
| Etanercept (25 mg vial) | 1st 6 months | 2nd 6 months | 1st 6 months | 2nd 6 months |
| Estimated number of vials per year | 104 | 104 | ||
| Estimated reimbursement cost per year | 12,313.86 € | 12,313.86 € | ||
| Estimated cost per six months (26 weeks) | 6,156.93 € | 6,156.93 € | 6,156.93 € | 6,156.93 € |
| Infliximab (100 mg vial) | 1st 6 months | 2nd 6 months | 1st 6 months | 2nd 6 months |
| Estimated number of vials per year | 11.5 | 8.1 | 8.8 | 8.8 |
| Infusion cost/IV infusion | 56.69 € | 56.69 € | ||
| Estimated reimbursement cost per year | 10,966.75 € | 9,794.14 € | ||
| Estimated cost per six months (26 weeks) | 6,446.38 € | 4,520.37 € | 4,897.07 € | 4,897.07 € |
| Rituximab (500 mg vial) | 1st 6 months | 2nd 6 months | 1st 6 months | 2nd 6 months |
| Estimated number of vials per year | 8.00 | 8.00 | ||
| Infusion cost/IV infusion | 56.69 € | 56.69 € | ||
| Estimated reimbursement cost per year | 10,202.76 € | 10,202.76 € | ||
| Estimated cost per six months (26 weeks) | 5,101.38 € | 5,101.38 € | 5,101.38 € | 5,101.38 € |
Based on 2008 acquisition costs and recommended dosing.